"Cost-Benefit Analysis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. Cost effectiveness compares alternative ways to achieve a specific set of results.
| Descriptor ID |
D003362
|
| MeSH Number(s) |
N03.219.151.125
|
| Concept/Terms |
Cost-Benefit Analysis- Cost-Benefit Analysis
- Analyses, Cost-Benefit
- Analysis, Cost-Benefit
- Cost-Benefit Analyses
- Cost Benefit Analysis
- Analyses, Cost Benefit
- Analysis, Cost Benefit
- Cost Benefit Analyses
Cost-Utility Analysis- Cost-Utility Analysis
- Analyses, Cost-Utility
- Analysis, Cost-Utility
- Cost Utility Analysis
- Cost-Utility Analyses
Economic Evaluation- Economic Evaluation
- Economic Evaluations
- Evaluation, Economic
- Evaluations, Economic
Marginal Analysis- Marginal Analysis
- Analyses, Marginal
- Analysis, Marginal
- Marginal Analyses
Cost Benefit- Cost Benefit
- Costs and Benefits
- Benefits and Costs
|
Below are MeSH descriptors whose meaning is more general than "Cost-Benefit Analysis".
Below are MeSH descriptors whose meaning is more specific than "Cost-Benefit Analysis".
This graph shows the total number of publications written about "Cost-Benefit Analysis" by people in this website by year, and whether "Cost-Benefit Analysis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1996 | 1 | 4 | 5 |
| 1997 | 3 | 4 | 7 |
| 1998 | 1 | 8 | 9 |
| 1999 | 1 | 6 | 7 |
| 2000 | 0 | 8 | 8 |
| 2001 | 2 | 8 | 10 |
| 2002 | 0 | 6 | 6 |
| 2003 | 0 | 6 | 6 |
| 2004 | 1 | 3 | 4 |
| 2005 | 1 | 7 | 8 |
| 2006 | 0 | 5 | 5 |
| 2007 | 2 | 10 | 12 |
| 2008 | 2 | 11 | 13 |
| 2009 | 1 | 10 | 11 |
| 2010 | 0 | 11 | 11 |
| 2011 | 0 | 13 | 13 |
| 2012 | 1 | 10 | 11 |
| 2013 | 1 | 11 | 12 |
| 2014 | 2 | 14 | 16 |
| 2015 | 2 | 13 | 15 |
| 2016 | 4 | 19 | 23 |
| 2017 | 6 | 8 | 14 |
| 2018 | 3 | 15 | 18 |
| 2019 | 6 | 16 | 22 |
| 2020 | 6 | 19 | 25 |
| 2021 | 5 | 15 | 20 |
| 2022 | 0 | 13 | 13 |
| 2023 | 1 | 10 | 11 |
| 2024 | 7 | 2 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cost-Benefit Analysis" by people in Profiles.
-
Optimal Stopping Ages for Colorectal Cancer Screening. JAMA Netw Open. 2024 Dec 02; 7(12):e2451715.
-
Management of monochorionic diamniotic twin gestation affected by Type-II selective fetal growth restriction: cost-effectiveness analysis. Ultrasound Obstet Gynecol. 2025 Jan; 65(1):39-46.
-
Characteristics of a cost-effective blood test for colorectal cancer screening. J Natl Cancer Inst. 2024 Oct 01; 116(10):1612-1620.
-
The tyranny of non-inferiority trials. Lancet Oncol. 2024 Oct; 25(10):e520-e525.
-
The Impact of Unrelated Future Medical Costs on Economic Evaluation Outcomes for Different Models of Diabetes. Appl Health Econ Health Policy. 2024 Nov; 22(6):861-869.
-
Cataloging health state utility estimates for Duchenne muscular dystrophy and related conditions. Health Qual Life Outcomes. 2024 Sep 02; 22(1):72.
-
Randomized Controlled Trial Based US Commercial Payor Cost-Effectiveness Analysis of Endoscopic Sleeve Gastroplasty Versus Lifestyle Modification Alone for Adults With Class I/II Obesity. Obes Surg. 2024 Sep; 34(9):3275-3284.
-
Cost effectiveness of commercial portable ex vivo lung perfusion at a low-volume US lung transplant center. Artif Organs. 2024 Nov; 48(11):1288-1296.
-
Sotorasib dosing and incremental cost ineffectiveness - implications and lessons for stakeholders. Nat Rev Clin Oncol. 2024 May; 21(5):331-332.
-
Endovascular Thrombectomy with or without Bridging Thrombolysis in Acute Ischemic Stroke: A Cost-Effectiveness Analysis. Neuroepidemiology. 2024; 58(1):47-56.